HWM
HRTX icon

HB Wealth Management’s Heron Therapeutics HRTX Stock Holding History

HB Wealth Management’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.8K Buy
13,583
+2,394
+21% +$1.92K ﹤0.01% 1714
2026
Q1 		$8.95K Buy
11,189
+888
+9% +$1.03K ﹤0.01% 1544
2025
Q4 		$13.4K Sell
10,301
-1,169
-10% -$1.44K ﹤0.01% 1397
2025
Q3 		$14.5K Buy
11,470
+1,383
+14% +$2.19K ﹤0.01% 1335
2025
Q2 		$20.9K Buy
10,087
+87
+0.9% +$178 ﹤0.01% 1153
2025
Q1 		$22K Hold
10,000
– – ﹤0.01% 1204
2024
Q4 		$15.3K Hold
10,000
– – ﹤0.01% 1067
2024
Q3 		$19.9K Hold
10,000
– – ﹤0.01% 967
2024
Q2 		$35K Buy
+10,000
New +$30.7K ﹤0.01% 913

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
CC
Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

HB Wealth Management's HRTX Position: Q2 2026 in Review

HB Wealth Management increased its Heron Therapeutics (HRTX) stake by 21% in Q2 2026, buying an estimated $1.92K and bringing the position to 13,583 shares worth $5.8K. The position accounts for ﹤0.01% of the portfolio, ranked #1714.

HB Wealth Management first reported a position in HRTX in Q2 2024 and has held it in 9 quarters since. The position peaked at $35K in Q2 2024. 163 funds tracked by Wall St. Rank hold HRTX as of Q2 2026.

  • HB Wealth Management held 13,583 shares of Heron Therapeutics worth $5.8K as of Q2 2026.
  • HB Wealth Management bought 2,394 Heron Therapeutics shares in Q2 2026, an estimated $1.92K.
  • Heron Therapeutics made up ﹤0.01% of HB Wealth Management's portfolio in Q2 2026, its #1714 holding.
  • HB Wealth Management first reported a position in Heron Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • HB Wealth Management's Heron Therapeutics position peaked at $35K in Q2 2024.
  • 163 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2026.

Based on HB Wealth Management's 13F filing for Q2 2026, filed 29 Jul 2026.